Northeast Investment Management Has $42.57 Million Stock Position in Eli Lilly and Company $LLY

Key Points

• Northeast Investment Management decreased its holdings in Eli Lilly and Company by 1.5%, owning 54,615 shares worth approximately $42.57 million at the end of the second quarter.
• In its most recent earnings report, Eli Lilly reported an EPS of $6.31, exceeding analysts' expectations, with a year-over-year revenue growth of 37.6%.
• Several institutional investors have significantly increased their positions in Eli Lilly, resulting in institutional ownership comprising 82.53% of the company's stock.

Northeast Investment Management lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.5% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 54,615 shares of the company's stock after selling 846 shares during the period. Eli Lilly and Company comprises about 1.8% of Northeast Investment Management's portfolio, making the stock its 15th biggest holding. Northeast Investment Management's holdings in Eli Lilly and Company were worth $42,574,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of LLY. WestEnd Advisors LLC raised its holdings in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department raised its holdings in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company during the 1st quarter worth $40,000. Finally, TD Capital Management LLC grew its position in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after acquiring an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Down 1.9%

NYSE LLY opened at $803.53 on Friday. The business's 50-day moving average price is $753.09 and its two-hundred day moving average price is $765.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The firm has a market capitalization of $760.51 billion, a PE ratio of 52.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 EPS. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Analysts Set New Price Targets

LLY has been the topic of a number of research reports. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Berenberg Bank restated a "hold" rating and set a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. Finally, DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $939.12.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.